-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Colorectal Cancer Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Hepatocellular Carcinoma Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Pancreatic Cancer Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RBS-2418 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Solid Tumor Drug Details: RBS-2418 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RBS-2418 in Adrenal Gland Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RBS-2418 in Adrenal Gland Cancer Drug Details: RBS-2418 is under development for treatment of solid...
-
Analyst Opinions
NewUnited Kingdom (UK) Bancassurance Distribution Dynamics and Future Market, 2023 Update
United Kingdom (UK) Bancassurance Distribution Market Overview Bancassurance represents a strategic alliance between banks and insurance companies, designed to offer customers the convenience of purchasing insurance products in conjunction with banking services. The banking channel accounts for the highest share of total personal and commercial lines distribution in 2023. App purchases through the bank channel increased with no other channel recording a higher proportion of purchases via apps. This could be because of banks’ intensified focus on digitalization, resulting in...
-
Thematic Analysis
NewStrategic Partnerships in Fintech – Thematic Intelligence
Strategic Partnerships in Fintech Thematic Report Overview Strategic partnerships for fintech companies can include traditional vendor relationships, new niche fintech partners, big tech partners, and/or bank-as-a-service of distribution arrangements with firms outside of financial services. The right partnership can deliver overnight scale via access to new markets or customers or neutralize a disintermediating threat.Moreover, working with proven partners and business models for distribution or as a tech partner will be more attractive. The ‘strategic partnerships in fintech’ thematic intelligence report...
-
Thematic Analysis
Social Media in Banking – Thematic Intelligence
Social Media in Banking Thematic Report Overview Social media companies will increasingly diversify away from their ad-funded business model in the face of increased regulatory scrutiny. Social media in banking thematic report maps out the prospects of social media giants for a deep assault on financial services, and how incumbent banks might respond. The report shares findings from GlobalData’s 2023 Financial Services Consumer Survey, which covers consumer openness to a wide variety of different types of financial services from different...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pucotenlimab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pucotenlimab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pucotenlimab in Triple-Negative Breast Cancer (TNBC) Drug Details: Pucotenlimab...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Camrelizumab (Airuika)...